drugset / Trial / NCT07680686

Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants

NCT07680686

Phase 1 Not yet recruiting 52 enrolled AbbVie
RandomizedCrossoverOpen-labelBasic science

Summary

This study will assess how different oral formulations of ubrogepant move through the body in healthy adult participants under fasting and fed conditions.

Timeline

Start
2026-06-30
Primary completion
2026-10
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ubrogepant Small molecule Oral

Indications

No indication recorded.